eMed’s cover photo
eMed

eMed

Health and Human Services

Miami, Florida 9,494 followers

eMed is the leading platform for employer-sponsored preemptive health management, delivering GLP-1 solutions.

About us

eMed Empathetic AI™ Population Health GLP-1 Platform lets the miracle of GLP-1s be enjoyed by your population. Clients include Employers, Government, Unions and NGOs. Learn more at eMed.com.

Website
emed.com
Industry
Health and Human Services
Company size
51-200 employees
Headquarters
Miami, Florida
Type
Privately Held
Founded
2020

Locations

Employees at eMed

Updates

  • eMed reposted this

    View organization page for eMed

    9,494 followers

    GLP-1 care shouldn’t be hard to access and it shouldn’t be complicated. So we’re making it easy and, most of all, human. Today we’re announcing our individualized GLP-1 program, offering GLP-1 care delivered to your home. It combines GLP-1 medication with 24/7 clinical support and weekly check-ins that keep you accountable and confident – all within the comfort of your own home. Here’s how it works. 1️⃣A screening kit arrives at your doorstep. Follow the guided blood collection with a telehealth proctor, and send it back to the lab with the included FedEx label. 2️⃣A clinician reviews your lab results. If you qualify, your medication is shipped directly to you. 3️⃣You begin your journey at home backed by weekly check-ins, 24/7 care from our clinical team and ongoing health tracking. We built our program to deliver real results. Over 65,000 people have joined us in the last year, and they lost an average of 21 pounds in six months. Eight out of ten have stayed on the program. And nearly all of them improved at least one biomarker, whether cholesterol, blood sugar or liver health. For a limited time, the complete eMed program is $99 per month. That includes clinical reviews, full program access, side-effect support and a complimentary clinical-grade blood kit. If prescribed, FDA-approved medication starts at $199. eMed supports you every step of the way so you stay on track. We know that when care is personalized and guided, people stick with it and see real results. That’s what we’re building at eMed. Or as we like to say: 𝗧𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝘆𝗼𝘂.  𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹. 𝗣𝗿𝗼𝘃𝗲𝗻. 𝗛𝘂𝗺𝗮𝗻. Wegovy ® and Ozempic ® are registered trademarks of Novo Nordisk A/S.   Zepbound ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.   All other trademarks, registered or unregistered, are the property of their respective owners.

  • View organization page for eMed

    9,494 followers

    Exciting news! Our individualized GLP-1 program represents everything that we’ve been working toward – making healthcare more accessible, more personal and wrapping care around people to help them start and stay on their journeys. Our mission just got bigger!

    View profile for Linda Yaccarino

    CEO of eMed Population Health | Chair of SheMed | Chair of YMU | Former CEO of X | Global Leader | Philanthropist

    Our mission just got bigger! My team and I talk to people every day who want to feel healthier but don’t know where or how to begin. They tell us GLP-1 weight-loss medications are financially out of reach and the care they receive is far too impersonal. When people do get access, they often find it’s too hard to stay on track without real support and, over time, they lose momentum. That’s why expanding access to GLP-1s matters so much. We’re proud to offer direct access to Novo Nordisk’s lower GLP-1 pricing, an important step forward in giving millions of people more control over their health. But access alone isn’t enough. People need care that fits into their real lives. And that’s where we, eMed, come in. We’re announcing our clinically guided GLP-1 program for anyone who has ever wished healthcare were easier to access, more personal and more human. Our goal: to bring together personalized care, the proven results of GLP-1s and the support that keeps you moving forward. Every decision is guided by medical experts and tailored to the individual. Real guidance from real people who help you stay on track. What began as a diabetes therapy is now one of the greatest medical advances in human health, helping people manage weight, improve their overall metabolic health and reduce cardiovascular and other risks. GLP-1s are now being studied for their potential to treat conditions such as PCOS, sleep apnea, and even cognitive decline. That's what we’re building at eMed. Or, as we like to say: 𝗧𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝘆𝗼𝘂.  𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹. 𝗣𝗿𝗼𝘃𝗲𝗻. 𝗛𝘂𝗺𝗮𝗻.

    • No alternative text description for this image
  • View organization page for eMed

    9,494 followers

    GLP-1 care shouldn’t be hard to access and it shouldn’t be complicated. So we’re making it easy and, most of all, human. Today we’re announcing our individualized GLP-1 program, offering GLP-1 care delivered to your home. It combines GLP-1 medication with 24/7 clinical support and weekly check-ins that keep you accountable and confident – all within the comfort of your own home. Here’s how it works. 1️⃣A screening kit arrives at your doorstep. Follow the guided blood collection with a telehealth proctor, and send it back to the lab with the included FedEx label. 2️⃣A clinician reviews your lab results. If you qualify, your medication is shipped directly to you. 3️⃣You begin your journey at home backed by weekly check-ins, 24/7 care from our clinical team and ongoing health tracking. We built our program to deliver real results. Over 65,000 people have joined us in the last year, and they lost an average of 21 pounds in six months. Eight out of ten have stayed on the program. And nearly all of them improved at least one biomarker, whether cholesterol, blood sugar or liver health. For a limited time, the complete eMed program is $99 per month. That includes clinical reviews, full program access, side-effect support and a complimentary clinical-grade blood kit. If prescribed, FDA-approved medication starts at $199. eMed supports you every step of the way so you stay on track. We know that when care is personalized and guided, people stick with it and see real results. That’s what we’re building at eMed. Or as we like to say: 𝗧𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝘆𝗼𝘂.  𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹. 𝗣𝗿𝗼𝘃𝗲𝗻. 𝗛𝘂𝗺𝗮𝗻. Wegovy ® and Ozempic ® are registered trademarks of Novo Nordisk A/S.   Zepbound ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.   All other trademarks, registered or unregistered, are the property of their respective owners.

  • View organization page for eMed

    9,494 followers

    Linda Yaccarino took the stage today at The Female Quotient’s AI Summit alongside Arianna Huffington, contributing to an important conversation on the future of AI-powered, people-centered care. At eMed, this commitment to people-centered care guides how we apply AI across population health by bringing solutions that support clinicians, improve outcomes, and help employers strengthen their benefit strategy. #eMed #eMedPopulationHealth #GLP1 #EmployeeBenefits

    View profile for Linda Yaccarino

    CEO of eMed Population Health | Chair of SheMed | Chair of YMU | Former CEO of X | Global Leader | Philanthropist

    I’ve spent most of my career working at the intersection of transformation and access — giving people the tools and technology to improve their lives while also championing their progress. That’s why I joined eMed and why today’s conversation with Arianna Huffington at the The Female Quotient’s AI Summit means so much. The rise of GLP-1 medications paired with the power of AI together form more than a medical shift. At eMed Health, our focus is simple: to make transformation accessible to everyone. Tap, test, talk and treat — all from home, in minutes. With the power of our AI platform, and our partnership with Thrive Global, we're delivering care that is personal, supportive, and rooted in empathy. Together, we’re building an end-to-end path that flips the script – from reactive care to prevention. They bring the soul — the habits, the mindset, the daily nudges — and we bring the clinical rigor and technology. As I shared with women professionals, leaders, innovators, and entrepreneurs in the room today, we have the chance to bend two curves: the health curve, by expanding access for millions, and the cost curve, which impacts every employer and every family. This is OUR moment and we're creating a movement. I’m grateful to everyone leaning in with us. They form the groundwork of an intensely human journey with profound life-changing implications, and we’re still at the beginning!

    • No alternative text description for this image
  • View organization page for eMed

    9,494 followers

    At eMed, our enduring mission has been to democratize access to GLP-1s, and we’re pleased to see that President Trump’s proposed GLP-1 plan aligns closely with our mission and goals. These new recommendations are crucial for ensuring that trusted, FDA-approved medications are accessible to all Americans, thereby eliminating the secondary counterfeit market. "This moment truly marks a pivotal turning point in the U.S., with obesity being recognized as one of the key drivers of chronic disease." - Dyan Hes, MD eMed will continue to collaborate with our partners to deliver the highest standard of clinical practice in obesity care, employing FDA-approved medications through our medically supervised, Empathetic AI platform. #eMed #eMedPopulationHealth #GLP1

    • No alternative text description for this image
  • View organization page for eMed

    9,494 followers

    eMed is meeting the moment.
 A solution being embraced. The conversation surrounding the peptide revolution is gaining momentum, and eMed is at the center of it. Our industry leading model focuses on what matters most: accessibility, transparency, and adherence. #HealthcareTransformation#PeptidePopulationHealth#GLP1#Adherence

  • View organization page for eMed

    9,494 followers

    Big news from eMed we’re partnering with Thrive Global to deliver an integrated, end-to-end obesity care program for employers. This partnership brings together eMed’s digital-first GLP-1 clinical management platform with Thrive Global’s science-backed behavior change and lifestyle technology, creating a comprehensive, evidence-based solution for sustainable results. By fusing medical innovation with real-time coaching and data-driven behavior support, we’re redefining what it means to deliver holistic preventive care. Together, we’re setting a new standard in employer benefits, driving better outcomes and long-term impact. Thank you, Arianna Huffington and the Thrive Global team for your visionary commitment to holistic health and lasting behavior change. Click here to learn more: https://lnkd.in/evhNV5a8 #eMed #eMedPopulationHealth #GLP1 #EmployeeBenefits

    • No alternative text description for this image
  • View organization page for eMed

    9,494 followers

    Game-changer for heart health: A new study led by John Deanfield CBE shows Wegovy reduces the risk of heart attack and stroke by 20% regardless of weight loss. This finding reframes how we view GLP-1s. It’s not just about weight loss, but about protecting heart health and addressing aging-related disease at the source. At eMed, we’re redefining population health through clinically supervised, on-label GLP-1/GIP programs that prioritize safety, outcomes, and accountability. Learn more about how clinical integrity and data-driven care are shaping the future of health: https://lnkd.in/ex6bZKGP #eMed #eMedPopulationHealth #GLP1 #EmployeeBenefits

  • View organization page for eMed

    9,494 followers

    Tune in live to see Linda Yaccarino, eMed CEO, on the panel of Zeta Global Live '25 today at 10:15am EST https://lnkd.in/dT-7JaNV

    View organization page for Zeta Global

    71,292 followers

    Our Zeta Live lineup just keeps getting bigger and better ✨ We’re thrilled to welcome even more bold visionaries and trailblazing leaders to the stage next week 🚀   The countdown is on – stay tuned for highlights as we explore the future of AI-powered marketing 🔥

  • View organization page for eMed

    9,494 followers

    We are thrilled to announce the appointment of Dyan Hes, MD as Chief Medical Officer. A board-certified pediatrician and Diplomate of the American Board of Obesity Medicine (ABOM), Dr. Hes will provide executive medical leadership, with a focus on improving outcomes in preemptive care management. In her role, Dr. Hes will advise clinical, product and technology teams on evidence-based care models, optimizing GLP-1 therapies for diverse patient populations at scale. While strengthening partnerships with business leaders and investors, she will also work to deliver measurable impact by demonstrating the potential reduction in medical care costs to employers and insurers. Read the full press release here: https://lnkd.in/ePuQZbeb #healthcareinnovation #PopulationHealth #GLP1 #ChronicCare

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

eMed 2 total rounds

Last Round

Corporate round

Investors

Aon
See more info on crunchbase